Literature DB >> 24903097

Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy.

Jordan S Pober1, Dan Jane-wit2, Lingfeng Qin2, George Tellides2.   

Abstract

Cardiac allograft vasculopathy is the major cause of late graft loss in heart transplant recipients. Histological studies of characteristic end-stage lesions reveal arterial changes consisting of a diffuse, confluent, and concentric intimal expansion containing graft-derived cells expressing smooth muscle markers, extracellular matrix, penetrating microvessels, and a host mononuclear cell infiltrate concentrated subjacent to an intact graft-derived luminal endothelial cell lining with little evidence of acute injury. This intimal expansion combined with inadequate compensatory outward remodeling produces severe generalized stenosis extending throughout the epicardial and intramyocardial arterial tree that causes ischemic graft failure. Cardiac allograft vasculopathy lesions affect ≥50% of transplant recipients and are both progressive and refractory to treatment, resulting in ≈5% graft loss per year through the first 10 years after transplant. Lesions typically stop at the suture line, implicating alloimmunity as the primary driver, but pathogenesis may be multifactorial. Here, we will discuss 6 potential contributors to lesion formation (1) conventional risk factors of atherosclerosis; (2) pre- or peritransplant injuries; (3) infection; (4) innate immunity; (5) T-cell-mediated immunity; and (6) B-cell-mediated immunity through production of donor-specific antibody. Finally, we will consider how these various mechanisms may interact with each other.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  T-lymphocytes; transplantation

Mesh:

Substances:

Year:  2014        PMID: 24903097      PMCID: PMC4324618          DOI: 10.1161/ATVBAHA.114.302818

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  64 in total

1.  Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.

Authors:  Birgit Fogal; Tai Yi; Chen Wang; Deepak A Rao; Amir Lebastchi; Sanjay Kulkarni; George Tellides; Jordan S Pober
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

Review 2.  Cardiac allograft vasculopathy.

Authors:  Michael S Lee; Will Finch; Giora Weisz; Ajay J Kirtane
Journal:  Rev Cardiovasc Med       Date:  2011       Impact factor: 2.930

3.  Transforming growth factor beta expression by human vascular cells inhibits interferon gamma production and arterial media injury by alloreactive memory T cells.

Authors:  A H Lebastchi; S F Khan; L Qin; W Li; J Zhou; N Hibino; T Yi; D A Rao; J S Pober; G Tellides
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

4.  Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients.

Authors:  Safa Kalache; Rajani Dinavahi; Sean Pinney; Anita Mehrotra; Madeleine W Cunningham; Peter S Heeger
Journal:  J Immunol       Date:  2011-06-15       Impact factor: 5.422

Review 5.  Novel roles of complement in T effector cell regulation.

Authors:  Peter S Heeger; Claudia Kemper
Journal:  Immunobiology       Date:  2011-07-13       Impact factor: 3.144

Review 6.  Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.

Authors:  M R Mehra
Journal:  Am J Transplant       Date:  2006-06       Impact factor: 8.086

7.  Reperfusion injury intensifies the adaptive human T cell alloresponse in a human-mouse chimeric artery model.

Authors:  Tai Yi; Birgit Fogal; Zhengrong Hao; Zuzana Tobiasova; Chen Wang; Deepak A Rao; Rafia S Al-Lamki; Nancy C Kirkiles-Smith; Sanjay Kulkarni; John R Bradley; Alfred L M Bothwell; William C Sessa; George Tellides; Jordan S Pober
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-03       Impact factor: 8.311

8.  Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice.

Authors:  M I Lorber; J H Wilson; M E Robert; J S Schechner; N Kirkiles; H Y Qian; P W Askenase; G Tellides; J S Pober
Journal:  Transplantation       Date:  1999-03-27       Impact factor: 4.939

9.  A key role for matrix metalloproteinases and neutral sphingomyelinase-2 in transplant vasculopathy triggered by anti-HLA antibody.

Authors:  Sylvain Galvani; Magali Trayssac; Nathalie Augé; Jean-Claude Thiers; Denis Calise; Hans-Willi Krell; Federico Sallusto; Nassim Kamar; Lionel Rostaing; Mogens Thomsen; Anne Nègre-Salvayre; Robert Salvayre
Journal:  Circulation       Date:  2011-11-14       Impact factor: 29.690

10.  Intimal fibrosis in human cardiac allograft vasculopathy.

Authors:  Manon Huibers; Nicolaas De Jonge; Joyce Van Kuik; Erica Siera-De Koning; Dick Van Wichen; Hub Dullens; Marguérite Schipper; Roel De Weger
Journal:  Transpl Immunol       Date:  2011-07-18       Impact factor: 1.708

View more
  31 in total

Review 1.  Transplant allograft vasculopathy: Role of multimodality imaging in surveillance and diagnosis.

Authors:  Gregory A Payne; Fadi G Hage; Deepak Acharya
Journal:  J Nucl Cardiol       Date:  2015-12-28       Impact factor: 5.952

Review 2.  Translational implications of endothelial cell dysfunction in association with chronic allograft rejection.

Authors:  Sarah Bruneau; Johannes Wedel; Fadi Fakhouri; Hironao Nakayama; Leo Boneschansker; Daniel Irimia; Kevin P Daly; David M Briscoe
Journal:  Pediatr Nephrol       Date:  2015-04-24       Impact factor: 3.714

3.  Complement C5 Inhibition Reduces T Cell-Mediated Allograft Vasculopathy Caused by Both Alloantibody and Ischemia Reperfusion Injury in Humanized Mice.

Authors:  L Qin; G Li; N Kirkiles-Smith; P Clark; C Fang; Y Wang; Z-X Yu; D Devore; G Tellides; J S Pober; D Jane-Wit
Journal:  Am J Transplant       Date:  2016-06-14       Impact factor: 8.086

4.  Imaging in patients with advanced therapies for heart failure.

Authors:  Joanna M Joly; Steven G Lloyd
Journal:  J Nucl Cardiol       Date:  2015-03-31       Impact factor: 5.952

Review 5.  Chronic allograft rejection: a fresh look.

Authors:  Johannes Wedel; Sarah Bruneau; Nora Kochupurakkal; Leo Boneschansker; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

Review 6.  The intragraft microenvironment as a central determinant of chronic rejection or local immunoregulation/tolerance.

Authors:  Johannes Wedel; Hironao Nakayama; Nora M Kochupurakkal; Josephine Koch; Michael Klagsbrun; Diane R Bielenberg; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

Review 7.  Recent advances in allograft vasculopathy.

Authors:  Jonathan Merola; Daniel D Jane-Wit; Jordan S Pober
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

8.  Disruption of the Gut Microbiota With Antibiotics Exacerbates Acute Vascular Rejection.

Authors:  Kevin Rey; Sukhbir Manku; Winnie Enns; Thea Van Rossum; Kevin Bushell; Ryan D Morin; Fiona S L Brinkman; Jonathan C Choy
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

9.  Endothelial Cell-Derived Interleukin-18 Released During Ischemia Reperfusion Injury Selectively Expands T Peripheral Helper Cells to Promote Alloantibody Production.

Authors:  Lufang Liu; Caodi Fang; Whitney Fu; Bo Jiang; Guangxin Li; Lingfeng Qin; Jacob Rosenbluth; Gavin Gong; Catherine B Xie; Peter Yoo; George Tellides; Jordan S Pober; Dan Jane-Wit
Journal:  Circulation       Date:  2019-11-20       Impact factor: 29.690

Review 10.  Acute and chronic phagocyte determinants of cardiac allograft vasculopathy.

Authors:  Kristofor Glinton; Matthew DeBerge; Xin-Yi Yeap; Jenny Zhang; Joseph Forbess; Xunrong Luo; Edward B Thorp
Journal:  Semin Immunopathol       Date:  2018-08-23       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.